Pharma set for prosperous 2018 as 44,500 attend CPhI Worldwide

Nov 15, 2017

CPhI Worldwide, organised by UBM, closes its 28th edition with pre-audit figures indicating a record-breaking attendance of over 44,500* and 2,598 exhibitors. Held in Frankfurt (Germany), the heart of Europe’s biggest pharmaceutical market (24-26th October, 2017), the world’s largest pharma event saw attendees from 169 countries – 25% of which are CEO or board level.   CPhI Worldwide is widely used as a barometer of pharma’s overall health, as it is the only platform that brings together global pharma, and a strong event is reflective of a prosperous pharma industry. Over 85% of attendance is international, with over 6,000people travelling ...

Read More

Romaco presents single-sided rotary press for bi-layer and effervescent tablets at P-MEC in Mumbai

Nov 14, 2017

The Romaco Group will demonstrate its extensive know-how regarding pharmaceutical applications with selected technologies for tableting and secondary packaging. The KTP 590X single-sided rotary press, the newest model in Romaco Kilian’s established KTP series, will be the main highlight at the exhibition stand. Romaco Kilian KTP 590X single-sided rotary press The KTP 590X is an extremely versatile single-sided rotary press from Romaco Kilian which can be used to manufacture both mono-layer and bi-layer tablet formats. It can be switched between mono-layer and bi-layer mode without any modifications to the compression units. Bi-layer tablets can be compressed at any time on the version with ...

Read More

Horizon Discovery’s Dharmacon introduces Edit-R CRISPRa reagent platform for genome-wide CRISPR activation

Nov 14, 2017

Horizon Discovery, a global leader in gene editing and gene modulation technologies, today announced the launch of its reagent platform for CRISPR activation (CRISPRa) from its recently acquired Dharmacon™ business. This is the latest addition to the Company’s market-leading Edit-R™ portfolio for CRISPR-Cas9 genome engineering.   The new Edit-R CRISPRa offering provides researchers interested in gain-of-function studies with a powerful and easy-to-use two-component system for drug discovery, disease modeling, or pathway analysis. The straightforward system is available in lentiviral and synthetic formats and is well-suited for robust over-expression in virtually any cell system. This format is also highly amenable to ...

Read More

Investment Plan for Europe: EIB grants financing to medneo

Nov 14, 2017

The European Investment Bank (EIB) will provide financing of EUR 30 million to medneo Group, a Berlin headquartered company providing innovative imaging diagnostics’ services and technology “as a service”. The financing will support medneo to enlarge its activities in the radiology sector, open additional radiology centres, increase process efficiency for its customers and so enable greater patient’s access to a high quality radiology service without the typical long waiting times and process inconveniences. The transaction with medneo was made possible by the support of the “European Fund for Strategic Investments” (EFSI). EFSI is the central pillar of the “Investment Plan ...

Read More

Poor aggregation will see ADC targets fail or face long delays

Nov 14, 2017

ADC Biotechnology (ADC Bio)‘s leading experts warn that best in class ADCs are being overlooked due to critical aggregation control problems. CDMOs are unable to develop products which are capable of working successfully in clinical testing or which are economically viable. The warning comes as more and more full service CDMOs are investing in conjugation and ADC facilities.   “There is a major challenge in the ADC pipeline that conventional manufacturers have not addressed and which pharma companies are obliged to work around. The ultimate problem is that you have a candidate that may look promising but in practice it ...

Read More